{"id":2418,"date":"2024-07-11T09:42:43","date_gmt":"2024-07-11T01:42:43","guid":{"rendered":"https:\/\/flcube.com\/?p=2418"},"modified":"2024-10-15T23:55:55","modified_gmt":"2024-10-15T15:55:55","slug":"novo-nordisk-partners-with-indonesias-bio-farma-to-boost-asia-pacific-diabetes-drug-production","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=2418","title":{"rendered":"Novo Nordisk Partners with Indonesia\u2019s Bio Farma to Boost Asia-Pacific Diabetes Drug Production"},"content":{"rendered":"\n

Novo Nordisk (NYSE: NVO<\/a>; CPH: NOVO-B<\/a>), the Danish pharmaceutical giant specializing in diabetes care, is expanding its insulin manufacturing presence in the Asia-Pacific region. The company has entered into a partnership with Indonesia\u2019s state-owned Bio Farma to collaborate on the production of diabetes medications. As per a memorandum of understanding, Novo Nordisk will bring its diabetes products and insulin manufacturing expertise to the table, while Bio Farma will provide local production facilities; further details of the agreement were not disclosed.<\/p>\n\n\n\n

Bio Farma is expected to supply the local market, which is significant given that Indonesia is currently home to 19.5 million people with diabetes, a number projected to increase to 28.6 million by 2045. The prevalence of diabetes in Indonesia is concerning, with an estimated 80% of patients having poorly controlled blood sugar levels, according to the country’s health authorities.<\/p>\n\n\n\n

In recent months, Novo Nordisk has been actively expanding its manufacturing capabilities, primarily to support the company’s new generation of GLP-1 targeted obesity and diabetes treatments. This expansion includes an investment of over USD 4 billion in its Denmark-based production facilities, and in February 2024, parent company Novo Holdings announced plans to acquire contract manufacturing organization (CMO) Catalent for USD 16.5 billion, which included the direct transfer of three of Catalent\u2019s manufacturing plants to Novo Nordisk.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Novo Nordisk (NYSE: NVO; CPH: NOVO-B), the Danish pharmaceutical giant specializing in diabetes care, is…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1250,148,860],"class_list":["post-2418","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cph-novo-b","tag-novo-nordisk","tag-nyse-nvo"],"yoast_head":"\nNovo Nordisk Partners with Indonesia\u2019s Bio Farma to Boost Asia-Pacific Diabetes Drug Production - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk (NYSE: NVO; CPH: NOVO-B), the Danish pharmaceutical giant specializing in diabetes care, is expanding its insulin manufacturing presence in the Asia-Pacific region. The company has entered into a partnership with Indonesia\u2019s state-owned Bio Farma to collaborate on the production of diabetes medications. As per a memorandum of understanding, Novo Nordisk will bring its diabetes products and insulin manufacturing expertise to the table, while Bio Farma will provide local production facilities; further details of the agreement were not disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=2418\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Partners with Indonesia\u2019s Bio Farma to Boost Asia-Pacific Diabetes Drug Production\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=2418\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-11T01:42:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-15T15:55:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2418#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2418\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Partners with Indonesia\u2019s Bio Farma to Boost Asia-Pacific Diabetes Drug Production\",\"datePublished\":\"2024-07-11T01:42:43+00:00\",\"dateModified\":\"2024-10-15T15:55:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2418\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CPH: NOVO-B\",\"Novo Nordisk\",\"NYSE: NVO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=2418#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2418\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=2418\",\"name\":\"Novo Nordisk Partners with Indonesia\u2019s Bio Farma to Boost Asia-Pacific Diabetes Drug Production - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-07-11T01:42:43+00:00\",\"dateModified\":\"2024-10-15T15:55:55+00:00\",\"description\":\"Novo Nordisk (NYSE: NVO; CPH: NOVO-B), the Danish pharmaceutical giant specializing in diabetes care, is expanding its insulin manufacturing presence in the Asia-Pacific region. The company has entered into a partnership with Indonesia\u2019s state-owned Bio Farma to collaborate on the production of diabetes medications. As per a memorandum of understanding, Novo Nordisk will bring its diabetes products and insulin manufacturing expertise to the table, while Bio Farma will provide local production facilities; further details of the agreement were not disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2418#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=2418\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2418#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Partners with Indonesia\u2019s Bio Farma to Boost Asia-Pacific Diabetes Drug Production\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Partners with Indonesia\u2019s Bio Farma to Boost Asia-Pacific Diabetes Drug Production - Insight, China's Pharmaceutical Industry","description":"Novo Nordisk (NYSE: NVO; CPH: NOVO-B), the Danish pharmaceutical giant specializing in diabetes care, is expanding its insulin manufacturing presence in the Asia-Pacific region. The company has entered into a partnership with Indonesia\u2019s state-owned Bio Farma to collaborate on the production of diabetes medications. As per a memorandum of understanding, Novo Nordisk will bring its diabetes products and insulin manufacturing expertise to the table, while Bio Farma will provide local production facilities; further details of the agreement were not disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=2418","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Partners with Indonesia\u2019s Bio Farma to Boost Asia-Pacific Diabetes Drug Production","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=2418","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-07-11T01:42:43+00:00","article_modified_time":"2024-10-15T15:55:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=2418#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=2418"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Partners with Indonesia\u2019s Bio Farma to Boost Asia-Pacific Diabetes Drug Production","datePublished":"2024-07-11T01:42:43+00:00","dateModified":"2024-10-15T15:55:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=2418"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CPH: NOVO-B","Novo Nordisk","NYSE: NVO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=2418#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=2418","url":"https:\/\/flcube.com\/?p=2418","name":"Novo Nordisk Partners with Indonesia\u2019s Bio Farma to Boost Asia-Pacific Diabetes Drug Production - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-07-11T01:42:43+00:00","dateModified":"2024-10-15T15:55:55+00:00","description":"Novo Nordisk (NYSE: NVO; CPH: NOVO-B), the Danish pharmaceutical giant specializing in diabetes care, is expanding its insulin manufacturing presence in the Asia-Pacific region. The company has entered into a partnership with Indonesia\u2019s state-owned Bio Farma to collaborate on the production of diabetes medications. As per a memorandum of understanding, Novo Nordisk will bring its diabetes products and insulin manufacturing expertise to the table, while Bio Farma will provide local production facilities; further details of the agreement were not disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=2418#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=2418"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=2418#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Partners with Indonesia\u2019s Bio Farma to Boost Asia-Pacific Diabetes Drug Production"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/2418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2418"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/2418\/revisions"}],"predecessor-version":[{"id":6851,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/2418\/revisions\/6851"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}